← All trials
NCT06370442
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2024
- Primary completion
- May 31, 2025
- Completion date
- Sep 1, 2025
- First posted
- Apr 17, 2024
- Last posted
- Apr 22, 2024
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- State University of New York, SyracuseLead sponsor
- State University of New York, SyracuseSponsor investigator
- State University of New York, SyracuseOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.